%0 Journal Article
%A Wang, Xiao
%A Freiesleben, Silka Dawn
%A Schneider, Luisa-Sophie
%A Preis, Lukas
%A Priller, Josef
%A Spruth, Eike Jakob
%A Altenstein, Slawek
%A Schneider, Anja
%A Fließbach, Klaus
%A Wiltfang, Jens
%A Hansen, Niels
%A Jessen, Frank
%A Rostamzadeh, Ayda
%A Duzel, Emrah
%A Glanz, Wenzel
%A Incesoy, Enise I
%A Bürger, Katharina
%A Janowitz, Daniel
%A Ewers, Michael
%A Perneczky, Robert
%A Rauchmann, Boris Stephan
%A Teipel, Stefan J
%A Kilimann, Ingo
%A Goerss, Doreen
%A Laske, Christoph
%A Munk, Matthias H J
%A Spottke, Annika
%A Roy, Nina
%A Heneka, Michael
%A Brosseron, Frederic
%A Wagner, Michael
%A Wolfsgruber, Steffen
%A Ramirez, Alfredo
%A Kleineidam, Luca
%A Stark, Melina
%A Peters, Oliver
%T Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.
%J Neurology
%V 103
%N 8
%@ 0028-3878
%C [Erscheinungsort nicht ermittelbar]
%I Ovid
%M DZNE-2024-01159
%P e209806
%D 2024
%X CSF biomarkers have immense diagnostic and prognostic potential for Alzheimer disease (AD). However, AD is still diagnosed relatively late in the disease process, sometimes even years after the initial manifestation of cognitive symptoms. Thus, further identification of biomarkers is required to detect related pathology in the preclinical stage and predict cognitive decline. Our study aimed to assess the association of neurogranin and β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) with cognitive decline in individuals with subjective cognitive decline (SCD).We enrolled participants with available neurogranin and BACE1 measurements in CSF from the DELCODE (DZNE-Longitudinal Cognitive Impairment and Dementia, Germany) cohort. The longitudinal change of Preclinical Alzheimer's Cognitive Composite score was assessed as the primary outcome in participants with SCD and controls. The secondary outcome was defined as conversion of SCD to mild cognitive impairment (MCI) during follow-up. Levels of neurogranin, BACE1, and neurogranin/BACE1 ratio across groups were compared by analysis of covariance after adjustment for demographics. The linear mixed-effects model and Cox regression analysis were applied to evaluate their association with cognitive decline and progression of SCD to MCI, respectively.A total of 530 participants (mean age: 70.76 ± 6.01 years, 48.7
%K Humans
%K Aspartic Acid Endopeptidases: cerebrospinal fluid
%K Amyloid Precursor Protein Secretases: cerebrospinal fluid
%K Female
%K Male
%K Cognitive Dysfunction: cerebrospinal fluid
%K Aged
%K Neurogranin: cerebrospinal fluid
%K Disease Progression
%K Biomarkers: cerebrospinal fluid
%K Longitudinal Studies
%K Middle Aged
%K Aged, 80 and over
%K Aspartic Acid Endopeptidases (NLM Chemicals)
%K Amyloid Precursor Protein Secretases (NLM Chemicals)
%K Neurogranin (NLM Chemicals)
%K BACE1 protein, human (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39303184
%R 10.1212/WNL.0000000000209806
%U https://pub.dzne.de/record/272342